Flaminia Garribba, Monica Mazzarino, Francesca Rossi, Francesco Botrè

Recovery of polar and non polar substances from the ultrafiltrate fraction of the EPO aliquot

Laboratorio Antidoping, Federazione Medico-Sportiva Italiana, Roma, Italy

INTRODUCTION

The procedure used in doping control for the detection of recombinant human erythropoietin (rhuEPO) is based on the urinary analysis of the EPO isoforms by isoelectric focusing, double blotting and chemiluminiscent detection. This method requires a large volume of urine (20 ml), to be concentrated by ultrafiltration through a membrane with a nominal weight cut off of 30,000 Da. In the case of samples requiring a confirmation analysis, with multiple replicates, the volume of urine could be a limiting factor; for this reason the goal of this study was to verify whether the ultrafiltrate fraction produced at the first stages of the pretreatment of urine samples for EPO analysis can be used for the analysis of low molecular weight drugs (anabolic agents, diuretics, stimulants, narcotics and beta blockers). The recovery of the different substances in the ultrafiltrate fraction was evaluated on spiked and real urines, analysed according to the ISO 17025 screening procedures of the laboratory of Rome.

EXPERIMENTAL SECTION

Isolation of ultrafiltrate fraction

To 20 ml of spiked urine 400 μ l of protease inhibitor ("Complete") and 2 ml of tris-(hydroxymthyl)-aminomethane hydrochloride (Tris-HCl) 3.75 M were added; the sample was then centrifugated for 10 min, filtrated by Steriflip and the filtrate fraction transferred to a Centricon plus 20 and centrifuged for 20 minutes.

Anabolic agents (steroids and beta-agonists) and beta-blockers

Two 3 ml aliquots of the filtrate fraction and two aliquots of 3 ml of the same spiked sample but without filtration were analysed using the following procedure: to 3 ml of urine 50 μ l of internal standard (17 α -methyltestosterone), 1 ml of 0.2 M phosphate buffer pH 7.4 and 30 μ l of beta-glucuronidase from E. coli were added and hydrolysis was performed for 1 h at 50 °C. The buffered solution was alkalinised with 1 ml of 0.1 M potassium carbonate solution to pH 8-9 and the anabolic agents were extracted with 10ml of tert-butylmethyl ether on a mechanical shaker for 5 minutes. After centrifugation, the etheral layer was transferred and evaporated to dryness under vacuum; the residue was derivatized by 50 μ l of N-methyl-N-trimethylsilyltrifluoroacetamide (MSTFA):NH₄I:Dithioerythreitol (1000:2:4 v/w/w).

Diuretics

Two aliquots of 3 ml of the filtrate fraction and two aliquots of 3 ml of the same spiked sample but without filtration were analysed using the following procedure: to 3 ml of urine 50 μ l of internal standard (indomethacine/mefruside), 800 μ l of 4 M carbonate/bicarbonate buffer solution to pH 10 and the basic drugs were extracted with 6ml of a mixture of chloroform:isopropanol:tert-butylmethyl ether (80:10:10) on a mechanical shaker for 5 minutes. After centrifugation, the etheral layer was transferred and evaporated to dryness under vacuum; the residue was dissolved in 100 μ l of formate/formic acid buffer 5 M and the acid agents were extracted with 6ml of a mixture of chloroform:isopropanol: tert-butylmethyl ether (80:10:10) on a mechanical shaker for 5 minutes. After centrated with 6ml of a mixture of chloroform:isopropanol: tert-butylmethyl ether (80:10:10) on a mechanical shaker for 5 minutes at agents were extracted with 6ml of a mixture of chloroform:isopropanol: tert-butylmethyl ether (80:10:10) on a mechanical shaker for 5 minutes. After centrifugation, the etheral layer was transferred and evaporated to dryness under vacuum; the residue was dissolved in 100 μ l of 5 minutes. After centrifugation, the etheral layer was transferred and evaporated to dryness under vacuum; the residue was derivatized by 200 μ l of a mixture of acetone/iodomethane (9/1) and 50 mg of anhydrous potassium carbonate for ten minutes at 100 °C.

Stimulants and narcotics

Two aliquots of 2 ml of the filtrate fraction and two aliquots of 2ml of the same spiked sample but without filtration were analysed using the following procedure: to 2 ml of urine 50 μ l of internal standard (diphenylamine), 0.2 ml of soda and 1 g of sodium chloride were added and stimulants were extracted with 2 ml of tert-butyl methyl ether on a mechanical shaker for 5 minutes. After centrifugation, the etheral layer was transferred and evaporated to dryness under vacuum and diluted in 50 μ L of tert-butylmethyl ether.

RESULTS AND DISCUSSION


The recovery data for some of the compounds studied are reported in Table 1. All data were normalized to the recovery values obtained by the reference procedure (no ultrafiltration). As it can be seen, the recovery was very low for the most polar substances. Some examples of the quantitative values obtained for threshold substances are given in Figure 1.

TABLE 1 Recovery data for representative anabolic agents, diuretics, beta-blockers, stimulants and narcotics.

Substances	Traditional	Filtrate	Substances	Traditional	Filtrate	Substances	Traditional	Filtrate
	(%)	(%)		(%)	(%)		(%)	(%)
Steroids			Diuretics			Stimulants		-
Bolasterone	100	73	Acetazolamide	100	95	Bromantan	100	49
Boldenone	100	72	Amiloride	100	76	Ethamivane	100	77
Chlormetandienone	100	59	Althiazide	100	53	Ethylefrine	100	80
4-chloro-4-androsten-3α- ol-17-one	100	55	Bendroflumethiazide	100	47	Pholedrine	100	74
Danazol m.	100	5	Benthiazide	100	41	Pemoline	100	87
2α-methyl-5α-androstan- 3α-ol-17-one	100	71	Brinzolamide	100	95	Amphetamine	100	55
Epioxandrolone	100	88	Bumetanide	100	97	Fentermine	100	62
Epitestosterone	100	77	Butizide	100	38	Cathine	100	20
Epitrenbolone	100	62	Canrenone	100	91	Niketamide	100	79
9α-fluoro-17,17-dimethyl- 18-norandrosta-4,13- diene-11β-ol-3-one	100	53	Clamide	100	55	Ephedrine	100	65
16β-OH-furazabol	100	41	Chlorthalidone	100	71	Fencamfamine	100	60
Epimetendiol	100	80	Chlorothiazide	100	94	MDMA	100	85
6β -OH-metandienone	100	85	Dichlorphenamide	100	92	Fenetilline	100	80
17α-methyl-5α- androstene-3α,17β-diolo	100	67	Dorzolamide	100	96	Pentazocine	100	68
17α-methyl-5β- androstene-3α,17β-diolo	100	78	Fenquinizone	100	94	Pipradol	100	94
Mibolerone	100	75	Furosemide	100	94	Caffeine	100	88
Norandrosterone	100	79	Hydrochlorthiazide	100	88	Pentetrazol	100	65
17α-ethyl-5β-estrane- 3α,17β-diolo	100	70	Indapamide	100	89	Methafetamine	100	38
Testosterone	100	95	Methylchlorthiazide	100	56	Narcotics		
3'-OHstanozolol	100	85	Piretanide	100	96	Morphine	100	69
Beta2-agonists			Probenecid	100	94	d,l-11-nor-9- carboxy-D9-THC	100	33
Salbutamol	100	90	Torasemide	100	87	Methylphenidate	100	98
Bambuterol	100	82	Triamterene	100	88	Oxycodone	100	46
Terbutaline	100	60	Xipamide	100	81	Oxymorfone	100	30
Salmeterol	100	70	Beta-blockers					
Fenoterol	100	88	Acebutolol	100	69			
Procaterol	100	55	Alprenolol	100	67			
Zeranol	100	68	Atenolol	100	68			
Clenbuterol	100	95	Betaxolol	100	69			
Antioestrogens			Bisoprolol	100	77			
Anastrozol	100	90	Carteolol	100	51			
Formestane	100	70	Carvedilol	100	32			
Exemestane	100	65	Celiprolol	100	77			

Conclusions

- Our results show that the concentration of some substances, and specifically those of the more polar compounds, decreased significantly following the ultrafiltration process.
- Our findings also suggest that the ultrafiltration fraction can be used, without the risk of false negative, only for the screening analysis of diuretics, some stimulants and beta-blockers.
- Finally, the data here presented suggest that the ultrafiltration fraction should not be used for confirmation of threshold substances (primarily norandrosterone, d,l-11-nor-9-carbossi-D9-THC and ephedrine).



Ultrafiltrate fraction

Whole urine

Figure 1. Quantitation of threshold substances: comparison between the data obtained on the whole urine and on the EPO ultrafiltrate fraction. Urine spiked with 2 ng of norandrosterone/ml and 2 ng of noretiocholanolone/ml (**A**); routine sample, with an elevated T/E ratio (**B**); urine spiked with 15 ng of d,l-11-nor-9-carboxy-D9-THC /ml (**C**).